Addition of Dr. Norman LaFrance strengthen further Jubilant DraxImage expertise
MONTREAL, Oct. 17, 2012 /PRNewswire/ - Jubilant DraxImage Inc. (hereinafter “JDI”), a Jubilant Life Sciences Company, is pleased to announce the appointment of Dr. Norman LaFrance as Vice President, Medical & Regulatory Affairs and Chief Medical Officer, Jubilant DraxImage Inc. with effect from October 16, 2012.
Dr. LaFrance has extensive and successful FDA and global clinical regulatory and market support experience; he directed the approval of Cardiolite®, Persantine® and Neurolite® while he worked at DuPont Merck. He is well known at the FDA and was selected in the 4th quarter of 2011 in a unanimous recommendation from all relevant industry trade organizations to be the industry’s representative to the FDA Medical Imaging Advisory Committee [MIDAC]. Dr. LaFrance also led regulatory and/or medical affairs functions while at Bracco, Celltech, Bausch & Lomb and Molecular Insight Pharmaceuticals. Dr. LaFrance supported and championed the RB-82 Generator while at Bracco and has well established productive relationships throughout the nuclear and medical communities and enjoys an excellent professional working collaboration with KOL’s.
Dr. LaFrance has both Bachelor of Science and Master of Engineering degrees in Nuclear Engineering & Science from Rensselaer Polytechnic Institute [RPI], Troy, New York. Dr. LaFrance also has an MD degree from the University of Arizona, College of Medicine, Tucson, AZ, including electives at Yale University, College of Medicine, New Haven, Connecticut and University of Nevada, College of Medicine, Reno, Nevada. Dr. LaFrance retains active medical licensure and is double Board Certified in both Nuclear Medicine and Internal Medicine where he has also attained Fellowship Honors. Dr LaFrance practiced medicine for over 10 years and he has previous experience as Clinical Director of Nuclear Medicine at Johns Hopkins where he held faculty appointments at Johns Hopkins School of Medicine in Radiology and Medicine and at the Johns Hopkins School of Public Health in Radiation/Health Sciences in addition to his appointment as Clinical Director of Nuclear Medicine at Johns Hopkins Hospital. At Hopkins, he was also a member of the Johns Hopkins Medical Institution’s IRB and Chairman of both the RDRC [Radioactive Drug Research Committee] and CRC [Clinical Radiation Committee - an IRB sub-committee].
Martyn Coombs, President of Jubilant DraxImage stated, " We are very pleased to welcome Norman, who has extensive experience in our industry, to join the JDI team. He is a seasoned executive with an impressive track record and I look forward to his contribution towards the achievement of our vision. "
About Jubilant DraxImage Inc.
Jubilant DraxImage Inc., a subsidiary of Jubilant Life Sciences, develops, manufactures and markets diagnostic and therapeutic radiopharmaceuticals for the global nuclear medicine marketplace. Jubilant DraxImage Inc.'s mission is to be a leading global provider of radiopharmaceuticals and value-added enabling technologies. Products include a proprietary line of lyophilized Technetium-99m kits (MAA, MDP, DTPA and Sestamibi). Jubilant DraxImage Inc. is also a leading supplier of I-131 radiopharmaceuticals in North America, used for the diagnosis and treatment of thyroid disorder and cancer. Jubilant DraxImage Inc. products are exported worldwide, with regulatory approvals in USA, South America, parts of Europe and South Asia. More information about Jubilant DraxImage is available at www.draximage.com.
SOURCE Jubilant DraxImage Inc.
